share_log
Breakings ·  Dec 4 05:05
Outlook Therapeutics® Announces Nice Recommendation of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment